Engineered immune cells take on liver cancer in early trial
NCT ID NCT07487402
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial will test a new type of cell therapy called Meta10-GPC3 CAR-T in 27 people with advanced liver cancer that cannot be surgically removed. The treatment involves taking a patient's own immune cells, modifying them to recognize and attack liver cancer cells, and giving them back by infusion. The main goal is to check safety, but researchers will also look for signs that the tumors shrink.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Meta10-GPC3 CAR-T cells (a type of immune cell therapy)
What this could lead to
If it works, this could point toward a new treatment option for advanced liver cancer that has not responded to other therapies.
What could go wrong
This is a very early, small trial (27 people) focused on safety, so it is unknown if the treatment will shrink tumors or improve survival. CAR-T therapy can cause serious side effects like cytokine release syndrome.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The first affiliated hospital of medical college of zhejiang university
Hangzhou, Zhejiang, 310000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••